Key result
An admission HbA1c level >5.7% in non-diabetic patients with acute coronary syndrome was significantly associated with a higher rate of major adverse cardiac events compared to those with normal HbA1c.
Why the study?
The role of HbA1c in predicting acute coronary syndrome outcomes remains controversial, with less known about its prognostic value in non-diabetic patients.
Does elevated HbA1c (≥5.7%) predict major adverse cardiac events in non-diabetic patients presenting with acute coronary syndrome?
Case-Control (n=68)
Yes
Does elevated HbA1c (≥5.7%) predict major adverse cardiac events in non-diabetic patients presenting with acute coronary syndrome?
Absolute Event Rate: 78.1% vs 27.8%
p-value: p=<0.001
In non-diabetic patients presenting with acute coronary syndrome, an admission HbA1c ≥5.7% is an independent predictor of major adverse cardiac events during the hospital stay.
Elevated HbA1c may identify higher-risk non-diabetic ACS patients; hypothesis-generating and requires prospective confirmation before clinical use.
Background: The role of HbA1C in predicting the outcomes of acute coronary syndrome remains controversial. Lesser is known about it in non-diabetic patients. Therefore authors conducted a study to seek association between the HbA1C levels and the clinical outcome in non-diabetic patients who presented with acute coronary syndrome. Objective of the study was to estimate HbA1C levels in population of prediabetics and non-diabetics and to document and correlate major adverse cardiac events in prediabetic and non-diabetics.Method: This case control study included consecutive patients (n=68) without known diabetes mellitus admitted with acute coronary syndrome (STEMI, NSTEMI, UA) at our hospital. HbA1c was measured on admission. The patients were divided into 2 groups according to their HbA1c level (group 1 HbA1c<5.7%, group 2 HbA1c>5.7%). The main outcome was MACE (major adverse cardiac events including cardiogenic shock, arrhythmia, heart failure).Results: There was no significant difference between baseline characteristics of both groups but complications were seen in higher number cases with HbA1c >5.7%. No significant difference in mortality was found. On analysis HbA1c >5.7% was found to be an independent predictor of MACE.Conclusion: HbA1C is a predictor of major adverse cardiac events. Measurement of HbA1C levels may improve risk assessment in such patients presenting with ACS.
No takes yet. Share an insight, caveat, or question.
Gadwalkar et al. (2020) conducted a case-control in Acute coronary syndrome (ACS) (n=68). HbA1c >5.7% (Prediabetes) vs. HbA1c <5.7% (Normal) was evaluated on Major adverse cardiac events (MACE) during hospital stay (p=<0.001). An admission HbA1c level >5.7% in non-diabetic patients with acute coronary syndrome was significantly associated with a higher rate of major adverse cardiac events compared to those with normal HbA1c.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: